Bausch & Lomb and Pfizer plan to collaborate on promoting both companies' prescription eye drugs in the US, aiming to significantly increase the support for the products, according to Reuters.
Bausch & Lomb and Pfizer plan to collaborate on promoting both companies' prescription eye drugs in the US, aiming to significantly increase the support for the products, according to Reuters.
The five-year agreement involves Pfizer's glaucoma drug Xalatan and three B&L products: Alrex for conjunctivitis, Lotemax for inflammatory conditions and the combined anti-inflammatory and anti-infective medicine Zylet.
Financial terms between the companies were not released.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here